Actavis PLC (NYSE:ACT) agreed to pay about $66 billion for Allergan Inc., the maker of the antiwrinkle treatment Botox, in the year’s biggest pharmaceutical deal. The cash-and-stock purchase, in which Actavis will pay $219 a share, also puts an end to Valeant Pharmaceuticals International Inc.’s months-long hostile takeover fight for Allergan, a move backed by activist investor Bill Ackman. Actavis plc (NYSE:ACT) belongs to Healthcare sector. Its net profit margin is -8.10% and weekly performance is 10.66%. On last trading day company shares ended up $269.60. Actavis plc (NYSE:ACT) distance from 50-day simple moving average (SMA50) is 12.96%.

AK Steel Holding Corporation (NYSE:AKS) on Nov. 6 said the U.S. International Trade Commission (ITC) reached an affirmative (4-1) final determination that the domestic industry producing non-oriented electrical steel (NOES) is materially injured by reason of dumped and subsidized imports from six countries. AK Steel Holding Corporation (NYSE:AKS) shares decreased -0.78% in last trading session and ended the day at $6.39. AKS Gross Margin is 7.20% and its return on assets is -1.90%. AK Steel Holding Corporation (NYSE:AKS) quarterly performance is -37.48%.

Virginia-based Versar Inc. (NYSEMKT:VSR) has announced that its wholly-owned subsidiary, VersarPPS, has received an additional $800,000 contract to supply chemical splash protection suits to the United Kingdom’s Department for International Development (DFID), for use in the event of an Ebola outbreak. Versar previously announced a protection contract of $5.1 million, bringing the total contract value to nearly $6 million. On 18 November, Versar Inc. (NYSEMKT:VSR) shares remains unchanged and was closed at $2.99. VSR EPS growth in last 5 year was -16.50%. Versar Inc. (NYSEMKT:VSR) year to date (YTD) performance is -38.10%.

Signal Genetics, Inc. (NASDAQ:SGNL) said on Friday that its third quarter revenues increased 32 percent year over year. For the three months ended Sept. 30, the Carlsbad, Calif.-based cancer diagnostics firm said that revenues rose to $1.3 million from $983,589 in the year-ago quarter. “During the third quarter, we continued to execute on our business strategy by significantly growing our revenue, extending a key partnership and expanding our leadership team,” Signal President and CEO Samuel Riccitelli said in a statement. Signal Genetics, Inc. (NASDAQ:SGNL) ended the last trading day at $3.20. Company weekly volatility is calculated as 5.14% and price to cash ratio as 1.57. Signal Genetics, Inc. (NASDAQ:SGNL) showed a weekly performance of 2.89%.

Allied Nevada Gold Corp. (NYSEMKT:ANV) declared the filing on SEDAR of a National Instrument 43-101 Technical Report signifying the succeeding report for the lately declared feasibility research for the Hycroft mill development project. Recently the firm declared a loss of $62.4 million in its Q3 of 2014. Allied Nevada Gold Corp. (NYSEMKT:ANV) shares moved up 22.16% in last trading session and ended the day at $2.04. ANV Gross Margin is 13.90% and its return on assets is -5.10%. Allied Nevada Gold Corp. (NYSEMKT:ANV) quarterly performance is -41.04%.